Icatibant Teva

Icatibant, the active ingredient in Icatibant Teva, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in adult patients, helping to reduce swelling and associated discomfort.

GNH USA supplies Icatibant Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, offering consistent quality and regulatory compliance for customers across the EU and other global markets, including procurement teams and specialty care centers.

Icatibant is a bradykinin B2 receptor antagonist used in the management of hereditary angioedema, a rare genetic disorder characterized by episodic swelling of the skin, gastrointestinal tract, and airway. - Hereditary angioedema (acute attacks): delivers rapid reduction of subcutaneous and submucosal swelling, relieving pain and improving airway patency during an HAE episode. - Hereditary angioedema type I (C1‑inhibitor deficiency): provides prompt symptom control, decreasing the duration and severity of attacks in patients lacking functional C1‑inhibitor. - Hereditary angioedema type II (dysfunctional C1‑inhibitor): offers fast alleviation of swelling, helping to prevent progression of attacks in patients with abnormal C1‑inhibitor activity.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection area. - Redness at injection site: localized erythema. - Swelling at injection site: transient edema. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of airway: swelling that may compromise breathing. - Severe hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count observed rarely. - Necrosis at injection site: tissue death at the injection area.

Before using Icatibant, healthcare professionals should consider several precautionary measures to ensure safe administration. - Assess hypersensitivity: check patient for known allergy to icatibant or formulation components. - Monitor cardiovascular status: observe for hypotension or tachycardia during and after injection. - Evaluate pregnancy: avoid use unless benefits outweigh potential risks, as safety data are limited. - Use with caution in renal impairment: adjust monitoring as drug clearance may be affected. - Review concomitant ACE inhibitor therapy: be aware of possible reduced efficacy or increased bradykinin effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines, influencing its effectiveness or safety profile.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and diminish icatibant’s benefit; avoid co‑administration when possible. - Angiotensin receptor blockers (ARBs): similar risk of altered bradykinin activity; consider alternative therapy.

Moderate Interactions (Monitor Closely): - Other bradykinin pathway agents: concurrent use may affect efficacy; monitor clinical response. - Subcutaneous biologics: may increase local injection site reactions; observe site carefully. - Antihistamines: may mask early signs of hypersensitivity; watch for delayed reactions. - Diuretics: may potentiate hypotensive effect; monitor blood pressure. - Beta‑blockers: may mask tachycardia signs of anaphylaxis; monitor closely.